Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 65

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 65
---
 such shares, securities, cash, assets or any other property whatsoever which the holder would
have been entitled to receive upon the happening of the applicable corporate event had the December 2024 Common Warrants and January 2025
Common Warrants been exercised immediately prior to the applicable corporate event. Upon the consummation of any Fundamental Transaction,
the Company shall exchange the December 2024 Common Warrants and January 2025 Common Warrants for consideration equal to the Black Scholes
Value of such portion of the December 2024 Common Warrants and January 2025 Common Warrants subject to exchange (collectively, the “Aggregate
Black Scholes Value”) in the form of, at the Company’s election (such election to pay in cash or by delivery of the Rights
(as defined below), a “Consideration Election”), either (I) rights (with a beneficial ownership limitation, mutatis mutandis)
(the “Rights”), convertible in whole, or in part, at any time, without the requirement to pay any additional consideration,
at the option of the Holder, into such Corporate Event Consideration applicable to such Fundamental Transaction equal in value to the
Aggregate Black Scholes Value issuable upon conversion of the Rights to be determined in increments of 10% (or such greater percentage
as the Holder may notify the Company from time to time) of the portion of the Aggregate Black Scholes Value attributable to such Shares
(the “Share Value Increment”), with the aggregate number of Shares issuable upon exercise of the Rights with respect to the
first Successor Share Value Increment determined based on 70% of the Closing Bid Price of the Shares on the date the Rights are issued
and on each of the nine subsequent Trading Days, in each case, the aggregate number of additional Shares issuable upon exercise of the
Rights shall be determined based upon a Share Value Increment at 70% of the Closing Bid Price of the Shares in effect for such corresponding
Trading Day (such ten (10) Trading Day period commencing on, and including, the date the Rights are issued, the “Rights Measuring
Period”), or (II) in cash; provided, that the Company shall not consummate a Fundamental Transaction if the Corporate Event Consideration
includes capital stock or other equity interest (the “Successor Shares”) either in an entity that is not listed on an Eligible
Market or an entity in which the daily share volume for the applicable Successor Shares for each of the twenty Trading Days prior to the
date of